Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

King Pharma Loses $548M in 4Q, Cites Buyout Costs

By Pharmaceutical Processing | February 26, 2009

BRISTOL, Tenn. (AP) — King Pharmaceuticals Inc. said Thursday it lost almost $550 million in the fourth quarter, largely due to the costs of acquiring rival Alpharma Inc. The company also lost patent protection on its painkiller Altace a year ago, which caused sales to drop. King reported a loss of $548.5 million, or $2.25 per share, for the last three months of 2008 compared with a profit of $42.8 million, or 18 cents per share, a year ago. The company bought Alpharma for $1.6 billion in December, bolstering its lineup of painkilling drugs. The buyout of Alpharma gives King control of the drug candidate Embeda. The product is a morphine-based painkiller for chronic pain. Embeda is intended to be abuse-resistant, with the effects of the morphine blocked if the pills are crushed, chewed or dissolved. Excluding the research and development charge and other one-time items, King said it earned $58.9 million, or 24 cents per share. That compares with an adjusted profit of $113 million, or 46 cents per share a year ago. Revenue fell 35 percent to $347.7 million from $533.3 million. On average, analysts expected a profit of 23 cents per share and $345.2 million in revenue, according to Thomson Reuters. Sales of Altace dropped to $14 million from $158 million a year ago, but sales of other top drugs were also flat or down. Revenue from the hemostatic product Thrombin-JMI fell to $57 million from $69 million and sales of painkiller Avinza edged up to $33 million from $32 million. Revenue from Levoxyl, a thyroid supplement, declined to $20 million from $32 million. Sales of muscle relaxant Skelaxin slipped to $113 million from $114 million. A U.S. District Court overturned the patents protection Skelaxin in January, paving the way for low-cost generics to enter the market. Earlier this month, King responded by saying it will restructure its business and cut 22 percent of its jobs. King lost $333.1 million, or $1.37 per share, for all of 2008. A year earlier, it reported a profit of $183 million, or 75 cents per share. Revenue slid 28 percent to $1.56 billion from $2.14 billion due to the patent loss for Altace and increasing generic competition to Thrombin-JMI.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE